



11-25-05

ITW

Express Mail No.: EV452775965US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Serial No.: 10/344,863  
Filed: February 11, 2003  
Attorney Docket: 11321-026-999

Application Serial No.: 10/630,633  
Filed: February 6, 2004  
Attorney Docket: 11321-017-999

Application Serial No.: 10/344,884  
Filed: February 11, 2003  
Attorney Docket: 11321-016-999

Application Serial No.: 10/517,157  
Filed: December 6, 2004  
Attorney Docket: 11321-0022-999

Application Serial No.: 10/429,283  
Filed: May 2, 2003  
Attorney Docket: 11321-021-999

Application Serial No.: 11/060,997  
Filed: February 17, 2005  
Attorney Docket: 11321-025-999

**TRANSMITTAL OF REVOCATION AND POWER OF ATTORNEY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Revocation and Power of Attorney executed by Klaus Veitinger, and by Detlef Thielgen, Members of Executive Board of Schwarz Pharma AG, on behalf of Schwarz Pharma AG, the Assignee of the entire right, title, and interest in the above-identified patent applications by virtue of Assignments as indicated on Annex A.

Applicant requests that the Revocation and Power of Attorney be made of record in the file of the above-identified patent applications.

It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: November 22, 2005

Respectfully submitted,  
by: *Jaqueline Benn*  
*Thomas G. Rowan* Reg. No. 43,492  
34,419  
Thomas G. Rowan (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

Enclosure



Express Mail No.: EV452775965US  
**POWER OF ATTORNEY**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Serial No.: 10/344,863  
Filed: February 11, 2003

Application Serial No.: 10/630,633  
Filed: February 6, 2004

Application Serial No.: 10/344,884  
Filed: February 11, 2003

Application Serial No.: 10/517,157  
Filed: December 6, 2004

Application Serial No.: 10/429,283  
Filed: May 2, 2003

Application Serial No.: 11/060,997  
Filed: February 17, 2005

**REVOCATION AND POWER OF ATTORNEY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Schwarz Pharma AG hereby revokes any and all previous powers and appoints:

☒ (A) Practitioners at Customer Number 20583,

**AND THE FOLLOWING ATTORNEY WHO IS NOT A PRACTITIONER AT THE ABOVE CUSTOMER NUMBER**

(B) Bradford Paul Schmidt, Registry No. 42,128, of Schwarz Pharma, Inc. whose address is  
6140 West Executive Drive, Mequon, Wisconsin 53092-4467

as his/her/its/their attorney(s) or agent(s) to prosecute the applications identified above, and to  
transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified applications to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
(Statement under 37 CFR 3.73(b) is applicable)

**SIGNATURE of Assignee of Record**

Date: October 21, 2005

Signature: Klaus Veitinger

Typed Name: Klaus Veitinger

Position/Title: Member of Executive Board

Date: October 24, 2005

Signature: Detlef Thielgen

Typed Name: Detlef Thielgen

Position/Title: Member of Executive Board

**Statement Under 37 C.F.R. 3.73(b)**

Schwarz Pharma AG states that it is:

☒ the assignee of the entire right, title, and interest;

in the patent applications identified above by virtue of either:

☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignments were recorded in the United States Patent and Trademark Office as indicated in Annex A.

☐ Copies of assignments or other documents in the chain of title are attached.  
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**ASSIGNEE: Schwarz Pharma AG**

Date:	<u>October 21, 2005</u>	Date:	<u>October 24, 2005</u>
Signature:	<u>Klaus Veitinger</u>	Signature:	<u>Detlef Thielgen</u>
Typed Name:	<u>Klaus Veitinger</u>	Typed Name:	<u>Detlef Thielgen</u>
Position/Title:	<u>Member of Executive Board</u>	Position/Title:	<u>Member of Executive Board</u>

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

☐ Total of      forms are submitted.



ANNEX A

<u>Application of</u>	<u>Serial No.</u>	<u>Filed</u>	<u>For</u>	<u>Confirmation No.</u>	<u>Unit</u>	<u>Examiner</u>	<u>Attorney Docket No.</u>	<u>Date Recorded</u>	<u>Reel/ Frame</u>
Rimpler et al.	10/344,863	February 11, 2003	Novel Pharmaceutical Composition	4926	1615	Retford O. Berko	11321-026-999 (Formerly 52514(48991))	February 11, 2003	014139/ 0588
Rimpler et al.	10/344,884	February 11, 2003	Novel Pharmaceutical Compositions for Administering N-0923	3489	1614	Cyville Delacroix Muirheid	11321-016-999 (Formerly 58515(48992))	February 11, 2003	014055/ 0705
Schollmayer, E.	10/429,283	May 2, 2003	Use of Rotigotine for Treating the Restless Leg Syndrome	8910	1614	To be assigned	11321-021-999 (Formerly 57649(48992))	October 20, 2003	014628/ 0451
Breitenbach, A.	10/517,157	December 6, 2004	Device for the Transdermal Administration of a Rotigotine Base	5686	1645	To be assigned	11321-022-999 (Formerly 62139(48992))	December 6, 2004	016583/ 0643
Breitenbach et al.	10/630,633	February 6, 2004	Hot Melt TTS for Administering Rotigotine	9056	1615	To be assigned	11321-017-999 (Formerly 58723(46701))	February 6, 2004	014952/ 0034
Scheller et al.	11/060,997	February 17, 2005	Use of Rotigotine for Treatment or Prevention of Dopaminergic Neuron Loss	5718	1614	To be assigned	11321-025-999 (Formerly 60916(48992))	February 17, 2005	016317/ 0944